The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod |
| October 06, 2020 | October 2020 Bond Updates |
|
STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study,... |
| View more at: https://www.prnewswire.com:443/news-releases/the-lancet-gastroenterology-and-hepatology-publishes-index-pharmaceuticals-results-of-the-phase-iib-study-with-cobitolimod-301146245.html |
| Related News |
|